# Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Source: https://onco.cc/trials/nct04417621/  
OnCo record `nct04417621` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Naporafenib, Trametinib, Ribociclib in melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma is a phase 2 interventional study registered as NCT04417621 by Novartis Pharmaceuticals, with 134 participants enrolled, started 2020-10-30 and due to reach its primary completion in 2027-02-02. Interventions recorded: LXH254, LTT462, Trametinib, Ribociclib. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04417621
- Phase: 2
- Setting: A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 134

## Sources

- ClinicalTrials.gov NCT04417621: https://clinicaltrials.gov/study/NCT04417621

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Naporafenib](https://onco.cc/drugs/naporafenib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Trametinib](https://onco.cc/drugs/trametinib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct04417621.json